Medicare reviewing over Dendreon cancer vaccine
The U.S. Medicare program said on Wednesday it was evaluating data on Dendreon Corp’s prostate cancer therapy to decide whether to cover the product for seniors nationwide.
The shares of Dendreon Corp. plummeted by 23% and became $25 after the news came and closed in on $32.33 on Nasdaq.
The Centers for Medicare & Medicaid Services (CMS) [...]
